Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading

MT newswireMT newswire2026/11/06 15:13
11:13 AM EST, 11/06/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts were 0.38% lower at 1,856.25 on the S&P Europe Select ADR Index late Friday morning. The index is down about 1.8% for the week so far. From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and telecommunications company Nokia (NOK), which rose 2.2% and 2% respectively. They were followed by 3D printer company Materialise (MTLS) and biotech firm BioNTech (BNTX), which increased 1.8% and 1% respectively. The decliners from continental Europe were led by medical device maker EDAP TMS (FOCL) and software firm SAP (SAP), which dropped 12% and 4% respectively. They were followed by consumer goods company Unilever (UL) and lender ING Group (ING), which decreased 2.1% and 1.7% respectively. The gainers from the UK were led by Autolus Therapeutics (AUTL) and biopharmaceutical company Amarin (AMRN), which advanced 2.8% and 2.4% respectively. They were followed by InterContinental Hotels Group (IHG), which was up 2%. The decliners from the UK and Ireland were led by Biodexa Pharmaceuticals (BDRX) and Trinity Biotech (TRIB), which fell 4.6% and 3.3% respectively. They were followed by medical device maker Smith & Nephew (SNN) and communications company WPP (WPP), which lost 3.1% and 2.5% respectively.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12